Khaleej Times · 13 minutes ago

UAE conditionally approves new Ultomiris use for immune-mediated kidney disease

10 Nov 2026 · Cairo time

The UAE just conditionally approved a new use for Ultomiris for immune-mediated kidney disease, after the prescription was first registered in the UAE in 2022 for the treatment of several rare diseases.The Emirates Drug Establishment (EDE) granted conditional approval for a new indication of AstraZeneca’s Ultomiris (ravulizumab) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease…

You may also like

Khaleej Times'Everyone has a role': UAE leaders say proud of how society handled regional challengesKhaleej TimesUAE CBSE board exams 2027: Class 10, 12 exams begin Feb 16; schools share planning tipsKhaleej TimesReaders love to hate villains, writers need to understand them, SIBF authors sayKhaleej TimesSharjah approves housing loans, grants for 1,100 families